Scarica l'app Stockscreener
0.6103
0.97%
-0.006
Pre-mercato:
.61
-0.0003
-0.05%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6163
Aprire:
$0.6208
Volume 24 ore:
383.26K
Relative Volume:
0.27
Capitalizzazione di mercato:
$24.18M
Reddito:
$1.04M
Utile/perdita netta:
$-67.50M
Rapporto P/E:
-0.3175
EPS:
-1.9222
Flusso di cassa netto:
$-60.67M
1 W Prestazione:
+0.05%
1M Prestazione:
+5.01%
6M Prestazione:
-81.89%
1 anno Prestazione:
-78.13%
Intervallo 1D:
$0.6103
$0.6507
Intervallo di 1 settimana:
$0.5901
$0.6507
Portata 52W:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Nome
Vistagen Therapeutics Inc
Settore
Industria
Telefono
650-577-3600
Indirizzo
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6103 | 24.18M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-17 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-17 | Downgrade | Maxim Group | Buy → Hold |
| 2025-12-17 | Downgrade | Stifel | Buy → Hold |
| 2025-12-17 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-12-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-08-07 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-07-22 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | Iniziato | Robert W. Baird | Outperform |
| 2021-02-18 | Iniziato | Jefferies | Buy |
| 2021-01-04 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | Iniziato | Maxim Group | Buy |
| 2018-02-08 | Reiterato | Chardan Capital Markets | Buy |
| 2017-03-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Vistagen Therapeutics Inc Borsa (VTGN) Ultime notizie
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Stockholders to Connect - ACCESS Newswire
If You Invested $1,000 in Vistagen Therapeutics Inc (VTGN) - Stock Titan
Momentum Shift: What is the implied volatility of Vistagen Therapeutics Inc2026 Technicals & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Layoff Tracker: Gossamer, BiomX Reveal Hefty Staff Cuts - BioSpace
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Vistagen Therapeutics, Inc. Announces Resignation of Mary Rotunno as Director, Effective April 1, 2026 - marketscreener.com
Vistagen (NASDAQ: VTGN) director Mary Rotunno resigns from board effective April 1, 2026 - Stock Titan
VistaGen Showcases Intranasal Pherine Pipeline in New Presentation - The Globe and Mail
User - The Chronicle-Journal
VistaGen at Stifel CNS Forum: Strategic Insights on Fasedienol By Investing.com - Investing.com Canada
Class Action Filed Against Vistagen Therapeutics, Inc. (VTGN)March 16, 2026 Deadline to JoinContact Levi & Korsinsky - PR Newswire
Vistagen (NASDAQ: VTGN) details pherine CNS pipeline in new presentation - Stock Titan
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, - GuruFocus
Bronstein, Gewirtz & Grossman LLC Urges Vistagen - GlobeNewswire
CLASS ACTION DEADLINE TONIGHT MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit Deadline Tonight - The Daily Tribune News
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, I - GuruFocus
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Vistagen Therapeutics, Inc. (VTGN) Eyes Breakthrough with Phase 3 Social Anxiety Trial - MSN
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. ... - Black Hills Pioneer
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, - GlobeNewswire
VTGN DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class Action - GlobeNewswire Inc.
VTGN UPCOMING DEADLINE ON MONDAY, MARCH 16: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics Investors of the Securities Class Action Lawsuit (2026-03-14) - Seeking Alpha
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 16, 2026 in Vistagen LawsuitVTGN - PR Newswire
VTGN DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Vistagen Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today - ACCESS Newswire
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Vistagen Therapeutics, Inc. Investors ... - Caledonian Record
VTGN DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages - GlobeNewswire
VTGN Shareholder Alert: Vistagen Therapeutics, Inc. - GlobeNewswire
2026-03-13 | VTGN DEADLINE REMINDER: Bronstein, Gewirtz & Grossman LLC Reminds Vistagen Therapeutics, Inc. Investors to Join the Class Action Lawsuit Today | NDAQ:VTGN | Press Release - Stockhouse
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Vistagen Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesVTGN - Sahm
Holzer & Holzer, LLC Reminds VTGN Investors of the March 16, 2026 Lead Plaintiff Deadline in the Vistagen Therapeutics, Inc. Securities Class Action - marketscreener.com
Holzer & Holzer, LLC Reminds VTGN Investors of the March - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
FinancialContentVTGN INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - FinancialContent
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) SHAREHOLDER - GlobeNewswire
VistaGen Announces Workforce Reduction to Extend Cash Runway - The Globe and Mail
VTGN SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Vistagen Therapeutics (VTGN) Investors of Securities Class Action Deadline on March 16, 2026 - Lelezard
Vistagen Therapeutics, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsVTGN - cnhinews.com
Does Vistagen Therapeutics Inc. stock trade at a discount to peersForecast Cut & Reliable Price Action Trade Plans - mfd.ru
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the ... - Bluefield Daily Telegraph
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, - GlobeNewswire
Vistagen Therapeutics, Inc. Files Form 8-K with SEC: Company Information, Stock Details, and Compliance Disclosures (March 2026) - Minichart
LEVI & KORSINSKY, LLP ADVISORY TO INSTITUTIONAL INVESTORS: CLASS ACTION AGAINST VISTAGEN THERAPEUTICS MAY IMPACT PORTFOLIO HOLDINGS - Morningstar
Aug Highlights: Will Vistagen Therapeutics Inc outperform during market ralliesIPO Watch & Long Hold Capital Preservation Tips - baoquankhu1.vn
Vistagen Therapeutics reduces workforce by 20 percent to manage costs - Investing.com South Africa
Vistagen Therapeutics (MEX:VTGN) NonCurrent Deferred Revenue : MXN3.17 Mil (As of Dec. 2025) - GuruFocus
Vistagen Therapeutics Implements 20% Workforce Reduction - TradingView
Vistagen Therapeutics cuts ~20% of workforce, expects PALISADE-4 topline H1 2026 and cash into 2027 - TradingView
Vistagen (VTGN) slashes workforce 20% to focus on PALISADE-4 Phase 3 trial - Stock Titan
Vistagen Therapeutics Inc Azioni (VTGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):